Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost
Introduction: Respiratory syncytial virus (RSV) bronchiolitis is among the leading causes of hospitalization in infants. Prophylaxis with palivizumab may reduce RSV infection, but its prescription is restricted to high-risk groups. The aim of the study is to retrospectively determine acute hospitali...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2020.594898/full |
id |
doaj-b6a1931e75d9413cbd05ba9304efc859 |
---|---|
record_format |
Article |
spelling |
doaj-b6a1931e75d9413cbd05ba9304efc8592021-01-18T06:02:32ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602021-01-01810.3389/fped.2020.594898594898Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization CostElena Bozzola0Claudia Ciarlitto1Stefano Guolo2Carla Brusco3Gennaro Cerone4Livia Antilici5Livia Schettini6Anna Lucia Piscitelli7Anna Chiara Vittucci8Renato Cutrera9Massimiliano Raponi10Alberto Villani11Pediatric and Infectious Diseases Unit, Bambino Gesù Children Hospital, Rome, ItalyPediatric and Infectious Diseases Unit, Bambino Gesù Children Hospital, Rome, ItalySanitary Direction, Bambino Gesù Children Hospital, Rome, ItalySanitary Direction, Bambino Gesù Children Hospital, Rome, ItalySanitary Direction, Bambino Gesù Children Hospital, Rome, ItalyPediatric and Infectious Diseases Unit, Bambino Gesù Children Hospital, Rome, ItalyPediatric and Infectious Diseases Unit, Bambino Gesù Children Hospital, Rome, ItalyPediatric and Infectious Diseases Unit, Bambino Gesù Children Hospital, Rome, ItalyPediatric and Infectious Diseases Unit, Bambino Gesù Children Hospital, Rome, ItalyPneumology Unit, Bambino Gesù Children Hospital, Rome, ItalySanitary Direction, Bambino Gesù Children Hospital, Rome, ItalyPediatric and Infectious Diseases Unit, Bambino Gesù Children Hospital, Rome, ItalyIntroduction: Respiratory syncytial virus (RSV) bronchiolitis is among the leading causes of hospitalization in infants. Prophylaxis with palivizumab may reduce RSV infection, but its prescription is restricted to high-risk groups. The aim of the study is to retrospectively determine acute hospitalization costs of bronchiolitis.Materials and methods: Infants aged 1 month−1 year, admitted to Bambino Gesù Children Hospital, Rome, Italy, with a diagnosis of bronchiolitis from January 1 till December 31, 2017, were included in the study.Results: A total of 531 patients were enrolled in the study, and the mean age was 78.75 days. The main etiologic agent causing bronchiolitis was RSV, accounting for 58.38% of infections. The total cost of bronchiolitis hospitalization was 2,958,786 euros. The mean cost per patient was significantly higher in the case of RSV (5,753.43 ± 2,041.62 euros) compared to other etiology (5,395.15 ± 2,040.87 euros) (p = 0.04).Discussion: The study confirms the high hospitalization cost associated with bronchiolitis. In detail, in the case of RSV etiology, the cost was higher compared to other etiology, which is likely due to the longer hospitalization and the more frequent admission to the intensive cure department.Conclusion: This study highlights that bronchiolitis is an important cost item even in a tertiary hospital and that cost-effective interventions targeting RSV are increasingly urgent.https://www.frontiersin.org/articles/10.3389/fped.2020.594898/fullbronchiolitisrespiratory syncitial viruscostpreventionhospitaalization |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elena Bozzola Claudia Ciarlitto Stefano Guolo Carla Brusco Gennaro Cerone Livia Antilici Livia Schettini Anna Lucia Piscitelli Anna Chiara Vittucci Renato Cutrera Massimiliano Raponi Alberto Villani |
spellingShingle |
Elena Bozzola Claudia Ciarlitto Stefano Guolo Carla Brusco Gennaro Cerone Livia Antilici Livia Schettini Anna Lucia Piscitelli Anna Chiara Vittucci Renato Cutrera Massimiliano Raponi Alberto Villani Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost Frontiers in Pediatrics bronchiolitis respiratory syncitial virus cost prevention hospitaalization |
author_facet |
Elena Bozzola Claudia Ciarlitto Stefano Guolo Carla Brusco Gennaro Cerone Livia Antilici Livia Schettini Anna Lucia Piscitelli Anna Chiara Vittucci Renato Cutrera Massimiliano Raponi Alberto Villani |
author_sort |
Elena Bozzola |
title |
Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost |
title_short |
Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost |
title_full |
Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost |
title_fullStr |
Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost |
title_full_unstemmed |
Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost |
title_sort |
respiratory syncytial virus bronchiolitis in infancy: the acute hospitalization cost |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pediatrics |
issn |
2296-2360 |
publishDate |
2021-01-01 |
description |
Introduction: Respiratory syncytial virus (RSV) bronchiolitis is among the leading causes of hospitalization in infants. Prophylaxis with palivizumab may reduce RSV infection, but its prescription is restricted to high-risk groups. The aim of the study is to retrospectively determine acute hospitalization costs of bronchiolitis.Materials and methods: Infants aged 1 month−1 year, admitted to Bambino Gesù Children Hospital, Rome, Italy, with a diagnosis of bronchiolitis from January 1 till December 31, 2017, were included in the study.Results: A total of 531 patients were enrolled in the study, and the mean age was 78.75 days. The main etiologic agent causing bronchiolitis was RSV, accounting for 58.38% of infections. The total cost of bronchiolitis hospitalization was 2,958,786 euros. The mean cost per patient was significantly higher in the case of RSV (5,753.43 ± 2,041.62 euros) compared to other etiology (5,395.15 ± 2,040.87 euros) (p = 0.04).Discussion: The study confirms the high hospitalization cost associated with bronchiolitis. In detail, in the case of RSV etiology, the cost was higher compared to other etiology, which is likely due to the longer hospitalization and the more frequent admission to the intensive cure department.Conclusion: This study highlights that bronchiolitis is an important cost item even in a tertiary hospital and that cost-effective interventions targeting RSV are increasingly urgent. |
topic |
bronchiolitis respiratory syncitial virus cost prevention hospitaalization |
url |
https://www.frontiersin.org/articles/10.3389/fped.2020.594898/full |
work_keys_str_mv |
AT elenabozzola respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT claudiaciarlitto respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT stefanoguolo respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT carlabrusco respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT gennarocerone respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT liviaantilici respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT liviaschettini respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT annaluciapiscitelli respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT annachiaravittucci respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT renatocutrera respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT massimilianoraponi respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost AT albertovillani respiratorysyncytialvirusbronchiolitisininfancytheacutehospitalizationcost |
_version_ |
1724333733689950208 |